A phase II study of oxaliplatin, capecitabine and bevacizumab in the treatment of metastatic colorectal cancer

被引：0
|
作者：
Hurwitz, H [1 ]
Fernando, N [1 ]
Yu, DH [1 ]
Morse, M [1 ]
Blobe, G [1 ]
Gockerman, J [1 ]
Odogwu, L [1 ]
Mahon, M [1 ]
Truax, R [1 ]
Franklin, A [1 ]
机构：
[1] Duke Univ, Durham, NC USA
来源：
ANNALS OF ONCOLOGY | 2005年 / 16卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：285 / 285
页数：1
相关论文
共 50 条
  • [41] Capecitabine and irinotecan with bevacizumab 2-weekly for metastatic colorectal cancer: the phase II AVAXIRI study
    Garcia-Alfonso, Pilar
    Chaves, Manuel
    Munoz, Andres
    Salud, Antonieta
    Garcia-Gonzalez, Maria
    Gravalos, Cristina
    Massuti, Bartomeu
    Gonzalez-Flores, Encarna
    Queralt, Bernardo
    Lopez-Ladron, Amelia
    Losa, Ferran
    Jose Gomez, Maria
    Oltra, Amparo
    Aranda, Enrique
    BMC CANCER, 2015, 15
  • [42] Phase I/II Study of Capecitabine Plus Oxaliplatin (XELOX) Plus Bevacizumab As First-line Therapy in Japanese Patients with Metastatic Colorectal Cancer
    Doi, Toshihiko
    Boku, Narikazu
    Kato, Ken
    Komatsu, Yoshito
    Yamaguchi, Kensei
    Muro, Kei
    Hamamoto, Yasuo
    Sato, Atsushi
    Koizumi, Wasaburo
    Mizunuma, Nobuyuki
    Takiuchi, Hiroya
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2010, 40 (10) : 913 - 920
  • [43] PHASE II STUDY OF THE COMBINATION OF BEVACIZUMAB (RHUMAB VEGF) AND OXALIPLATIN PLUS CAPECITABINE (XELOX) IN PATIENTS WITH ADVANCED COLORECTAL CANCER
    Sarmiento, R.
    Frustaci, S.
    Torino, F.
    Ravaioli, A.
    Mattioli, R.
    Gebbia, V.
    Veri, A.
    Gasparini, G.
    ANNALS OF ONCOLOGY, 2008, 19 : 144 - 144
  • [44] Phase II study of the combination of bevacizumab (Rhumab VEGF) and oxaliplatin plus capecitabine (Xelox) in patients with advanced colorectal cancer
    Sarmiento, R.
    Frustaci, S.
    Bonadonna, A.
    Ravaioli, A.
    Oliviero, G.
    Mattioli, R.
    Tarnburrano, T.
    Gebbia, V
    Agueli, R.
    Torino, F.
    Lo Noce, V
    Veri, A.
    Gasparini, G.
    ANNALS OF ONCOLOGY, 2008, 19 : 85 - 86
  • [45] Phase II study of weekly irinotecan and capecitabine treatment in metastatic colorectal cancer patients
    Li, Wenhua
    Xu, Jianming
    Shen, Lin
    Liu, Tianshu
    Guo, Weijian
    Zhang, Wen
    Chen, Zhiyu
    Zhu, Xiaodong
    Li, Jin
    BMC CANCER, 2014, 14
  • [46] Phase II study of weekly irinotecan and capecitabine treatment in metastatic colorectal cancer patients
    Wenhua Li
    Jianming Xu
    Lin Shen
    Tianshu Liu
    Weijian Guo
    Wen Zhang
    Zhiyu Chen
    Xiaodong Zhu
    Jin Li
    BMC Cancer, 14
  • [47] Phase II study of capecitabine plus oxaliplatin for the first-line treatment of patients with metastatic colorectal carcinoma
    Xu, R.
    Li, Y.
    Luo, H.
    Wang, F.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [48] OXALIPLATIN AND CAPECITABINE (XELOX) PLUS BEVACIZUMAB (BEVA) FOR ELDERLY PATIENTS (PTS) WITH METASTATIC COLORECTAL CANCER (mCRC): BOXE, A PHASE II TRIAL
    Rosati, Gerardo
    Cordio, Stefano
    Leo, Silvana
    Daniele, Bruno
    Butera, Alfredo
    ANNALS OF ONCOLOGY, 2011, 22 : v104 - v104
  • [49] Phase I study of dasatinib in combination with capecitabine, oxaliplatin and bevacizumab followed by an expanded cohort in previously untreated metastatic colorectal cancer
    Strickler, John H.
    McCall, Shannon
    Nixon, Andrew B.
    Brady, John C.
    Pang, Herbert
    Rushing, Christel
    Cohn, Allen
    Starodub, Alexander
    Arrowood, Christy
    Haley, Sherri
    Meadows, Kellen L.
    Morse, Michael A.
    Uronis, Hope E.
    Blobe, Gerard C.
    Hsu, S. David
    Zafar, S. Yousuf
    Hurwitz, Herbert I.
    INVESTIGATIONAL NEW DRUGS, 2014, 32 (02) : 330 - 339
  • [50] Phase I study of dasatinib in combination with capecitabine, oxaliplatin and bevacizumab followed by an expanded cohort in previously untreated metastatic colorectal cancer
    John H. Strickler
    Shannon McCall
    Andrew B. Nixon
    John C. Brady
    Herbert Pang
    Christel Rushing
    Allen Cohn
    Alexander Starodub
    Christy Arrowood
    Sherri Haley
    Kellen L. Meadows
    Michael A. Morse
    Hope E. Uronis
    Gerard C. Blobe
    S. David Hsu
    S. Yousuf Zafar
    Herbert I. Hurwitz
    Investigational New Drugs, 2014, 32 : 330 - 339
12345